Ligand Pharmaceuticals | LGND - Selling And Administration Expenses

Stock Price
213.21
Daily Change
-5.77 -2.63%
Monthly
-4.49%
Yearly
103.95%
Q2 Forecast
208.92

Ligand Pharmaceuticals reported $20.84M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Baxter International USD 728M 33M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Enviri Corporation USD 104.1M 10.81M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.67B 180M Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 50.84M 7.53M Mar/2026